<DOC>
	<DOCNO>NCT00864513</DOCNO>
	<brief_summary>This study patient pancreatic cancer grow and/or spread previously receive standard chemotherapy drug call gemcitabine . In study drug call pemetrexed test . This drug approve FDA use lung cancer mesothelioma . The purpose study see pemetrexed keep pancreas cancer grow and/or spread gemcitabine grow . Subjects receive pemetrexed IV every 21 day disease progression unacceptable side effect occur .</brief_summary>
	<brief_title>Study Pemetrexed Second-Line Pancreas Cancer</brief_title>
	<detailed_description>This open label Phase II trial use pemetrexed second-line treatment patient advance pancreatic cancer progress within six month prior gemcitabine-based therapy . Subjects receive pemetrexed 500 mg/m2 IV every 21 day disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm adenocarcinoma pancreas Prior treatment distant locally advanced disease gemcitabinebased therapy Measurable evaluable disease ECOG performance status 02 Adequate hematological parameter Adequate baseline liver function At least 28 day major surgery At least 2 week last radiation treatment Must recover reversible toxicity prior chemotherapy Must able discontinue nonsteroidal antiinflammatory medication Must willing receive intramuscular vitamin B12 shot take oral folate supplement Any prior treatment pemetrexed More one prior chemotherapy regimen HIV positive antiretroviral therapy Pregnant lactate Prior organ allograft On concurrent antitumor therapy include radiation therapy chemotherapy Creatinine clearance 45 ml/min less Absolute neutrophil count &lt; 1500 Platelets &lt; 75,000 Bilirubin &gt; 1.5 time upper limit normal Transaminases &gt; 3 time upper limit normal except know liver metastasis wherein may &lt; /= 5 time upper limit normal Clinically significant ascites pleural effusion drain Any medical psychiatric condition may interfere ability comply protocol treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>pancreas</keyword>
	<keyword>metastatic</keyword>
	<keyword>recurrent</keyword>
</DOC>